Page 1 | Search Results | Blood | American Society of Hematology

Skip to Main Content

Skip Nav Destination

1-3 of 3

Sort by

Sort Order Select

Journal Articles

Novel von willebrand factor targeting thrombolytic TGD001 is safe and well tolerated in a phase 1 first-in-human trial

Marie Scully, Spero Cataland, Paul Coppo, Paul Knoebl, Paul Brinkkoetter, Javier de la Rubia, Marielle Klein Hesselink, Josefin-Beate Holz, Flora Peyvandi

Blood (2025) 146 (Supplement 1): 849.

https://doi.org/10.1182/blood-2025-849

Published: 2025

Journal Articles

Alternate-Day Dosing of Caplacizumab for Immune-Mediated Thrombotic Thrombocytopenic Purpura

Lucas Kühne, Dennis A. Eichenauer, Paul Knöbl, Linus A. Völker, Jessica Kaufeld, Ralph Wendt, Holger Hägele, Thomas Osterholt, Marcus Bieringer, Veronika Buxhofer-Ausch, Jan Menne, Ulf Schoenermarck, Paul Brinkkoetter

Blood (2021) 138 (Supplement 1): 2087.

https://doi.org/10.1182/blood-2021-151283

Published: 2021

Journal Articles

Caplacizumab Is Effective in Treating Immune-Mediated Thrombotic Thrombocytopenic Purpura in Real-World Scenarios and May Lower Mortality: An Aggregative Analysis

Linus A. Völker, Gesa Balduin, Lucas Kühne, Jessica Kaufeld, Ulf Schönermarck, Jan Menne, Paul Knöbl, Paul Brinkkoetter

Blood (2021) 138 (Supplement 1): 1019.

https://doi.org/10.1182/blood-2021-153211

Published: 2021